These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 12418607)

  • 21. Cognitive function in schizophrenia: conflicting findings and future directions.
    Moustafa AA; Garami JK; Mahlberg J; Golembieski J; Keri S; Misiak B; Frydecka D
    Rev Neurosci; 2016 Jun; 27(4):435-48. PubMed ID: 26756090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.
    Neill JC; Grayson B; Kiss B; Gyertyán I; Ferguson P; Adham N
    Eur Neuropsychopharmacol; 2016 Jan; 26(1):3-14. PubMed ID: 26655189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG
    Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.
    Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First- and second-generation antipsychotic medication and cognitive processing in schizophrenia.
    Weickert TW; Goldberg TE
    Curr Psychiatry Rep; 2005 Aug; 7(4):304-10. PubMed ID: 16098285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Important steps in the development of cognitive-enhancing drugs in schizophrenia.
    Buchanan RW
    Am J Psychiatry; 2006 Nov; 163(11):1867-9. PubMed ID: 17074932
    [No Abstract]   [Full Text] [Related]  

  • 28. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.
    Meltzer HY; McGurk SR
    Schizophr Bull; 1999; 25(2):233-55. PubMed ID: 10416729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?
    Meltzer HY; Sumiyoshi T
    Behav Brain Res; 2008 Dec; 195(1):98-102. PubMed ID: 18707769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study.
    Rémillard S; Pourcher E; Cohen H
    Schizophr Res; 2005 Dec; 80(1):99-106. PubMed ID: 16162401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses.
    de Bartolomeis A; Balletta R; Giordano S; Buonaguro EF; Latte G; Iasevoli F
    Psychiatry Res; 2013 Dec; 210(2):387-95. PubMed ID: 23910239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement of cognitive dysfunction after treatment with second-generation antipsychotics.
    Weiss E; Kemmler G; Fleischhacker WW
    Arch Gen Psychiatry; 2002 Jun; 59(6):572-3; author reply 573-5. PubMed ID: 12044210
    [No Abstract]   [Full Text] [Related]  

  • 33. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms.
    Kasper S
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S135-41. PubMed ID: 16872809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antipsychotics in the treatment of schizophrenia: an overview.
    Tandon R
    J Clin Psychiatry; 2011; 72 Suppl 1():4-8. PubMed ID: 22217436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Research progress in mechanisms and clinical application for blonanserin and lurasidone in improving cognitive function of schizophrenia].
    Zheng Q; Liu B; Xu S; Liao M; Zhang Y; Li L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Apr; 42(4):476-480. PubMed ID: 28490709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia.
    Meltzer HY; Bobo WV; Lee MA; Cola P; Jayathilake K
    Psychiatry Res; 2010 May; 177(3):286-93. PubMed ID: 20378185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006 Sep; 67(9):e11. PubMed ID: 17081078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.
    Levin ED; Rezvani AH
    Biochem Pharmacol; 2007 Oct; 74(8):1182-91. PubMed ID: 17714691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment.
    Sharma T; Antonova L
    Psychiatr Clin North Am; 2003 Mar; 26(1):25-40. PubMed ID: 12683258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.